Nicotinamide Riboside Clinical Trial for GWI

Recruiting now · Not applicable · Has a placebo group

Conditions studied: Gulf War Illness

In brief

In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).

Key facts

Study ID

NCT05243290

Run by

Roskamp Institute Inc.

People needed

52

Starts

2022-04-13

Expected to finish

2025-12-31

Last updated by the study team

2025-07-24

Who can join

Age: 47 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Both sexes, all ethnic groups, and ages 47 to 70 years.
• Subject willing and able to give informed consent.
• Medically stable as per the investigator's discretion.
• Negative urine pregnancy test for females of childbearing potential. A woman is considered of childbearing potential unless she is surgically sterile (hysterectomy or tubal ligation) or is postmenopausal (no menstrual cycle for 2 years or more).
• If female of childbearing potential, must be willing to use adequate birth control during the study and for 30 days after the last dose. Females agreeing to take an acceptable form of birth control per investigator discretion (where relevant). Females must prevent pregnancy or otherwise be unable to conceive.
• Veterans deployed to the Gulf War between August 1990 and August 1991.
• Veteran meets criteria for the CDC Chronic Multisymptom Illness (CMI) GWI definition or Kansas GWI definition.
• Weight of 50.0kg - 200.0kg (110 lbs. - 440 lbs.).

You may not qualify if…

• Diagnosed by a physician with medical or psychiatric conditions that would account for their symptoms or interfere with their ability to report their symptoms, as per investigator discretion.
• Female subject is either pregnant or nursing; or if female subject is of childbearing age is not currently on or is unwilling and/or unable to use birth control.
• Have contraindications, allergy, or sensitivity to NR, vitamin B3, or excipients (microcrystalline cellulose, silicon dioxide, magnesium stearate, hypromellose, and/or titanium dioxide).
• Any significant medical condition that could interfere with study conduct, as per investigator discretion. These may include but are not limited to the following: untreated chronic hypertension (defined as systolic > 180 mmHg; diastolic >110 mmHg), myocardial infarction within 6 months of screening, renal failure, hepatic failure, and/or receiving chemotherapy.
• Clinically significant lab values for clinical laboratory assessments, as per investigator discretion.
• Poor venous access.
• Current use of any NR supplement products (such as nicotinamide, nicotinamide mononucleotide (NMN), vitamin B3/Niacin, vitamin B complex, etc.) within 30 days of screening.
• Participation in another clinical trial involving dietary or pharmaceutical intervention within 90 days of screening.

Where it is running

• Nova Southeastern University — Fort Lauderdale, Florida, United States (enrolling)
• The Roskamp Institute — Sarasota, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.